ArticlePloS one2025
Identification of the immune-associated enhancer RNA SATB1-AS1 as a novel biomarker for thymic cancer prognosis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo screen key enhancer RNAs (eRNAs) in thymoma (THYM) through The Cancer Genome Atlas (TCGA) database and explore their potential as prognostic molecules and therapeutic targets in THYM.
methodsGene expression RNA-seq profiles of 33 cancer types were retrieved and downloaded from the TCGA database, and Kaplan-Meier survival analysis and Spearman correlation analysis were applied to screen eRNAs and target genes associated with survival in THYM patients. The correlation of target eRNAs with clinical features was assessed. Gene set enrichment analysis was performed to investigate the potential biological functions of target eRNAs. Finally, the prognostic potential of the eRNA was validated in other cancer types.
resultsIn THYM, SATB1-AS1 and the target gene SATB1 high expression were associated with a positive patient prognosis, and SATB1-AS1 expression was negatively correlated with patient stage (P < 0.05). Gene and pathway enrichment analyses revealed that SATB1-AS1 was associated with leukocyte transendothelial migration, natural killer cell-mediated cytotoxicity, neutrophil extracellular trap formation, PD-L1 expression and the PD-1 checkpoint pathway in cancer.
conclusionSATB1-AS1 may be a key eRNA in THYM and has the potential to be a marker and therapeutic target for the early diagnosis and prognosis of THYM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.